Vivos Therapeutics Founder & Chief Medical Officer Releases New Book Highlighting His Groundbreaking Work
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced the release of a new book by its Founder and Chief Medical Officer, Dr. G. Dave Singh, aimed at helping medical professionals understand craniofacial conditions affecting sleep health. The book, titled Pneumopedics and Craniofacial Epigenetics, explores the link between dentofacial anomalies and obstructive sleep apnea (OSA). Vivos’ technology offers a non-invasive treatment for mild-to-moderate OSA, now proven effective in over 17,000 patients. The book serves as a culmination of Dr. Singh's research and aims to advance understanding of innovative therapy options.
- Dr. Singh's book enhances understanding of craniofacial conditions and their link to OSA.
- Vivos' proprietary technology offers a non-surgical, cost-effective treatment for mild-to-moderate OSA.
- The book supports Vivos' scientific foundation and promotes awareness of its treatment approach.
- None.
HIGHLANDS RANCH, Colo., May 26, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that the Company’s Founder and Chief Medical Officer, Dr. G. Dave Singh, DMD, Ph.D., DDSc., has released a new book to help doctors and dentists better understand how to address underlying craniofacial conditions that affect a patient’s overall airway, breathing and sleep health.
Dr. Singh’s book, titled, Pneumopedics and Craniofacial Epigenetics, covers craniofacial growth and developmental genetics, and addresses the connection between dentofacial anomalies and developmental deficiencies closely associated with downstream conditions such as OSA. The book further cements the scientific and biological foundation upon which the Company’s proprietary approach rests. Vivos believes this approach, which combines the skills of specially trained dentists in cooperation with their medical colleagues, represents the first non-surgical, non-invasive and cost-effective treatment for people with mild-to-moderate OSA. By harnessing biomimetic and epigenetic principles, Dr. Singh describes not only why this technology works but also how it works.
The book’s foreword was written by Dr. Clete Kushida, MD, Ph.D., Division Chief and Medical Director, Stanford Sleep Medicine; Neurologist and Professor, Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center; and Director, Stanford Center for Human Sleep Research, Stanford University.
“In many respects, this book is the culmination of my life’s work and research, starting with the theoretical foundation set forth in the Spatial Matrix Hypothesis that I first published in 2004 and continuing through the ensuing years with numerous confirmational patient studies in clinical settings,” said Dr. Singh, who holds doctorate degrees in dental medicine, orthodontics and craniofacial development. “Having the opportunity to bring this technology to the world to help patients who are suffering continues to be my mission, and the overarching goal with this book is to spread the word far and wide about how this technology can truly make a difference in how we approach thinking about and treating downstream health conditions like OSA moving forward.”
Dr. Singh is a leading professor and researcher in the sleep medicine field. He has published over 200 articles in peer-reviewed medical, dental and orthodontic literature, as well as seven books/chapters. His pioneering research led to the development of the patented DNA appliance® and mRNA appliance® technology, now owned and distributed by Vivos.
Pneumopedics and Craniofacial Epigenetics is available on Amazon.
About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 17,000 patients worldwide by more than 1,200 dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.
For more information, visit www.vivoslife.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the anticipated benefits of the Company’s technology as described herein) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC's website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Investor Relations Contact:
Edward Loew
Investor Relations Officer
(602) 903-0095
ed@vivoslife.com
Media Relations Contact:
Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (212) 896-1231
ckasunich@kcsa.com / jrobles@kcsa.com
FAQ
What is the focus of Vivos Therapeutics as announced on May 26, 2021?
Who released a new book related to Vivos Therapeutics on May 26, 2021?
What are the key themes of Dr. Singh's book?
How many patients have benefited from Vivos' oral appliance technology?
What type of treatment does Vivos Therapeutics offer for obstructive sleep apnea?
